Early-stage non-small cell lung cancer is a potentially curable disease, but with relapse rates exceeding 50% with standard treatments, this is a patient population in critical need of therapy innovation. Immunotherapy with immune checkpoint blockade has revolutionized the treatment strategy for advanced lung cancer. However, the role of this therapy in earlier-stage disease is largely unknown. The study of immunotherapy in earlier-stage disease has many advantages, including assessment of pathologic response and incorporation of translational scientific analyses to evaluate antitumor immune responses. Multiple clinical trials are currently under way, with promising early results.

中文翻译：

---

早期肺癌中的PD-1阻断。

早期非小细胞肺癌是一种可以治愈的疾病，但是标准疗法的复发率超过50％，这是急需治疗创新的患者群体。带有免疫检查点封锁的免疫疗法彻底改变了晚期肺癌的治疗策略。然而，这种疗法在早期疾病中的作用在很大程度上尚不清楚。在早期疾病中进行免疫治疗的研究具有许多优势，包括评估病理反应和整合转化科学分析以评估抗肿瘤免疫反应。目前正在进行多项临床试验，并取得了可喜的早期结果。